Business Wire

NY-GENESIS

29.4.2022 15:17:05 CEST | Business Wire | Press release

Share
Genesis Q1 2022 Report Reflects Another Strong Quarter Amid Market Uncertainty

Genesis , a digital asset industry pioneer and digital currency prime brokerage, today released its Q1 2022 Market Observations Report , highlighting major trends across institutional digital asset markets. The report provides a breakdown of Genesis’ lending, derivatives, spot, and custody activities across Q1 2022, along with in-depth insight from the Genesis lending and derivatives desks on trends such as the growing adoption of permissioned DeFi protocols, the gradual institutionalization in debt markets and the continued growing interest from the traditional financial community in stablecoin derivatives.

The first quarter was characterized by Genesis’ notable growth across most of its operations – including another record quarter in derivatives trading activity – even against the backdrop of lower overall crypto market volumes and high levels of uncertainty throughout most asset types. Highlights during the quarter include the following:

  • In Q1 2022, the USD amount of active loans outstanding grew to $14.6 billion against declining prices, a level 17% higher than at the end of the previous quarter, and 62% higher than at the end of Q1 2021.
  • As of March 31, cumulative loan originations had reached $195 billion.
  • The notional volume traded by the derivatives desk in Q1 reached $27.8 billion, up 33% from Q4, inclusive of negotiated block- and exchange- traded futures.
  • Assets under custody increased by 23% over Q1.
  • The USD volume of assets moved from Genesis Custody to the Genesis trading or lending desks increased by 141% vs Q4 2022.
  • Genesis’ headcount increased 22% over the quarter to reach 208 employees across three continents.

“Institutions continue to develop their crypto strategies and strengthen their understanding of this industry, even amid the market uncertainty that has marked the start to this year,” said Michael Moro, CEO of Genesis. “As we continue to deepen engagement with our clients across Genesis’ wide range of products, we are committed to further expanding our market share and delivering innovative strategies for clients to access this growing asset class.”

Derivatives and Spot Trading

Genesis saw another record quarter in derivatives trading activity, with over $27.8 billion in notional value traded globally. This figure includes bilateral OTC, negotiated block futures trades and exchange-traded volumes, representing 33% quarter-on-quarter growth. In Q1, Genesis was also #1 in market share for blocked BTC and ETH Deribit-cleared derivatives via Paradigm with over $6.6 billion transacted1 . The firm also printed the first ever ETH and BTC Micro options trades on the CME in March. Additionally, the Genesis derivatives desk traded 61 different assets in the first quarter, with $4.7 billion notional traded in altcoin derivatives – Genesis’ highest quarterly total yet as it continues to prove its ability to help clients hedge and take directional positions in even the most esoteric of markets.

The Genesis spot desk traded over $11.4 billion in volume in Q1, with the continuing trend toward greater diversification of assets. BTC comprised 48% of the traded volume, in line with last quarter, while ETH saw a drop from 33% to 23% of total traded volume in Q1. The Genesis spot desk also saw a notable increase in activity across assets such as LUNA, SOL, AVAX, ZEC, LINK, ATOM and GALA.

Crypto Lending

Despite a market environment faced with many uncertainties, as valuations across all crypto assets nearly halved from November peaks, the Genesis lending desk originated over $44.3 billion in loans in Q1 2022, bringing cumulative originations since inception in March 2018 to $195 billion. Active loans outstanding also climbed to $14.6 billion to close the quarter, up 17% from the end of 2021.

The strong level of activity Genesis saw in Q1 – despite the weak market environment – was mainly due to organic volume driven by new institutions entering the industry and by increasing demand for cash loans, which allowed Genesis to capitalize on its core competitive strengths as a leading digital asset prime broker.

Custody

Assets under custody increased by 23% quarter-on-quarter, while the USD volume of assets moved from Genesis Custody to the Genesis trading or lending desks increased by 141% over the same period. This comes as Genesis continues to integrate its lending and trading desks more tightly into its SOC 2 Type 1-audited and FCA-registered custodian.

The number of customers onboarded to Genesis Custody also increased by 36% over the quarter, driven mainly by large public and private mining companies, venture capital firms and other traditional asset managers on a global level, following Genesis’ FCA registration and the roll out of its 24/5 support.

The Genesis Q1 2022 Market Observations Report provides a comprehensive look into key market activity through insights from the firm’s spot trading, derivatives trading, lending, custody, treasury and prime brokerage businesses. To read the full Q1 2022 Market Observations Report, click here .

About Genesis

Genesis is a full-service digital currency prime brokerage providing a single point of access for select qualified individuals and global institutional investors. Genesis combines unrivaled operational excellence, a seamless user experience, and best-in-class client service to provide the full suite of services global investors require to manage their digital asset portfolios.

The firm offers sophisticated market participants a fully integrated platform to trade, borrow, lend, and custody digital assets, creating new opportunities for yield while increasing capital efficiency for counterparties.

Genesis is a wholly owned subsidiary of Digital Currency Group (DCG) , one of the largest private investors in blockchain and digital asset companies.

For more information on Genesis, please visit genesistrading.com and follow @GenesisTrading on Twitter.

____________________________
1 Per Paradigm statistics as of April 28, 2022

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye